Zhejiang Haizhou Pharmaceutical Co.,Ltd
Zhejiang Haizhou Pharmaceutical Co., Ltd. is a Chinese pharmaceutical manufacturer established in 1970 that operates from Yanhai Industrial Park in Taizhou (Zhejiang). The facility spans about 35 acres and is organized around three primary product segments: Guaiacol derivatives, Epichlorohydrin derivatives, and iodine contrast media. The company provides a broad portfolio of products and services on a global scale, including Active Pharmaceutical Ingredients (API), intermediates, fine chemicals, and contract manufacturing services.
Quality and compliance underpin Zhejiang Haizhou Pharmaceutical’s operations. The company holds ISO 9001, ISO 14001, and OHSAS 18001 certifications, and its API production adheres to cGMP standards. Certifications and approvals from major regulatory bodies, including SFDA (China FDA), US-FDA, and EDQM, reflect a quality-focused approach to pharmaceutical manufacturing. This framework ensures that processes align with international regulatory expectations across multiple markets.
In addition to its manufacturing capabilities, Zhejiang Haizhou Pharmaceutical emphasizes a structured contract manufacturing model. The organization maintains a professional project team and multifunctional workshop environments to support both GMP and non-GMP contract services. Through these capabilities, the company engages in long-term collaborations with global pharmaceutical enterprises, providing flexible manufacturing solutions that accommodate a range of client requirements.
The company’s business model centers on developing and delivering pharmaceutical intermediates, APIs, and related fine chemicals, with an emphasis on reliability, regulatory compliance, and scalable production capacity. Zhejiang Haizhou Pharmaceutical’s integrated approach—combining technical expertise, validated processes, and a global orientation—positions it to support customers seeking secure supply chains and consistent product quality in the pharmaceutical sector.
